Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 2, 1998, Pages 920-928

  Hartmann, Gunther ^a   Krug, Anne ^a   Bidlingmaier, Martin ^a   Hacker, Ulrich ^a   Eigler, Andreas ^a   Albrecht, Richard ^b   Strasburger, Christian J ^a   Endres, Stefan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE;

ARTICLE; CONFOCAL MICROSCOPY; DRUG UPTAKE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; LYMPHOCYTE; MONOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL;

FLOW CYTOMETRY; HUMANS; LYMPHOCYTES; MONOCYTES; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHATIDYLETHANOLAMINES;

EID: 0031836186     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Bayever E, Iversen PL, Bishop MR, Sharp JG, Tewary HK, Arneson MA, Pirruccello SJ, Ruddon RW, Kessinger A and Zon G (1993) Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: Initial results of a phase I trial. Antisense Res Dev 3:383-390.
2. Beltinger C, Saragovi HU, Smith RM, Lesauteur L, Shah N, Dedionisio L, Christensen L, Raible A, Jarett L and Gewirtz AM (1995) Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 95:1814-1823.
3. Benimetskaya L, Loike JD, Khaled Z, Loike G, Silverstein SC, Cao L, Khoury JE, Cai TQ and Stein C (1997) Mac 1 (cdllb/cd18) is an oligodeoxynucleotide binding protein. Nat Med 3:414-420.
4. Bennett CF, Chiang MY, Chan H, Shoemaker JE and Mirabelli CK (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 41:1023-1033.
5. Bøyum A (1968) Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 21:77-89.
6. Bradbury J (1997) Antisense drugs move towards the clinic. Lancet 349:259.
7. Caplen NJ, Alton EW, Middleton PG, Dorin JR, Stevenson BJ, Gao, X, Durham SR, Jeffery PK, Hodson ME and Coutelle C (1995) Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1:39-46.
8. Cohen J (1995) AIDS therapy. New hope against blindness. Science 268:368-369.
9. Eigler A, Sinha B, Hartmann G and Endres S (1997) Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 18:487-492.
10. Endres S, Fülle HJ, Sinha B, Stoll D, Dinarello CA, Gerzer R and Weber PC (1991) Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-α and interleukin-1β by human mononuclear cells. Immunology 72:56-60.
11. Farrell CM and Lukens LN (1995) Naturally occurring antisense transcripts are present in chick embryo chondrocytes simultaneously with the down-regulation of the α 1 (I) collagen gene. J Biol Chem 270:3400-3408.
12. Feigner J, Bennet F and Feigner PF (1993) Cationic lipid-mediated delivery of polynucleotides. Methods Compan Methods Enzymol 5:67-75.
13. Fisher TL, Terhorst T, Cao X and Wagner RW (1993) Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells. Nucleic Acids Res 21:3857-3865.
14. Giles RV, Spiller DG and Tidd DM (1995) Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res Dev 5:23-31.
15. Hartmann G, Bidlingmaier M, Jahrsdorfer B and Endres S (1997) Oligonucleotides: Extrapolating from in vitro to in vivo [letter]. Nat Med 3:702-702.
16. Hartmann G, Bidlingmaier M, Jahrdörfer B, Krug A, Hacker U, Eigler A and Endres S (1998) Oligonucleotide uptake in leukocytes is dependent on extracellular calcium: a hint for the involvement of adhesion molecules? Nucleosides Nucleotides in press.
17. Hartmann G, Krug A, Eigler A, Moeller J, Murphy J, Albrecht R and Endres S (1996a) Specific suppression of human tumor necrosis factor-α synthesis by antisense oligodeoxynucleotides. Antisense Nucl Acid Drug Dev 6:291-299.
18. Hartmann G, Krug A, Waller-Fontaine K and Endres S (1996b) Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: Dependence on phosphorothioate modification and reversal by heparin. Mol Med 2:429-438.
19. Hawkins JW (1995) Oligonucleotide therapeutics: Coming 'round the clubhouse turn. Antisense Res Dev 5:1.
20. Iversen PL, Crouse D, Zon D and Perry D (1992a) Binding of antisense phosphorothioate oligonucleotides to murine lymphocytes is lineage specific and inducible. Antisense Res Dev 2:223-233.
21. Iversen PL, Zhu S, Meyer A and Zon G (1992b) Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res Dev 2:211-222.
22. Kimelman D and Kirschner MW (1989) An antisense mRNA directs the covalent modification of the transcript encoding fibroblast growth factor in Xenopus oo-cytes. Cell 59:687-696.
23. Krieg AM, Gmelig MF, Gourley MF, Kisch WJ, Chrisey LA and Steinberg AD (1991) Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. Antisense Res Dev 1:161-171.
24. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA and Klinman DM (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549.
25. Liang H, Nishioka Y, Reich CF, Pisetsky DS and Lipsky PE (1996) Activation of human B cells by phosphorothioate oligodeoxynucleotides. J Clin Invest 98:1119-1129.
26. Marti G, Egan W, Noguchi P, Zon G, Matsukura M and Broder S (1992) Oligodeoxyribonucleotide phosphorothioate fluxes and localization in hematopoietic cells Antisense Res Dev 2:27-39.
27. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D and Chang AE (1993) Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 90:11307-11311.
28. Nestle FO, Mitra RS, Bennett CF, Chan H and Nickoloff BJ (1994) Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J Invest Dermatol 103:569-575
29. Neurath MF, Pettersson S, Meyer zum Büschenfelde KH and Strober W (1996) Local administration, of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med 2:998-1004
30. Nichols GL (1995) Antisense oligodeoxynucleotides as therapeutic agents for chronic myelogenous leukemia. Antisense Res Dev 5:67-69.
31. Pirruccello SJ, Perry GA, Bock PJ, Lang MS, Noel SM, Zon G and Iversen PL (1994) HIV-1 rev antisense phosphorothioate oligonucleotide binding to human mononuclear cells is cell type specific and inducible. Antisense Res Dev 4:285-289.
32. Redekop GJ and Naus CC (1995) Transfection with bFGF sense and antisense cDNA resulting in modification of malignant glioma growth. J Neurosurg 82:83-90.
33. Skorski T, Nieborowska SM, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, Zon G and Calabretta B (1994) Suppression of Philadelphial leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 91:4504-4508.
34. Stein CA, Tonkinson JL, Zhang LM, Yakubov L, Gervasoni J, Taub R and Rotenberg SA (1993) Dynamics of the intern alization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry 32:4855-4861.
35. Temsamani J, Kubert M, Tang J, Padmapriya A and Agrawal S (1994) Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs. Antisense Res Dev 4:35-42.
36. Tonkinson JL, Guvakova M, Khaled Z, Lee J, Yakubov L, Marshall WS, Caruthers MH and Stein CA (1994) Cellular pharmacology and protein binding of phosphoromonothioate and phosphorodithioate oligodeoxynucleotides: A comparative study. Antisense Res Dev 4:269-278.
37. Vandendriessche T, Chuah MK, Chiang L, Chang HK, Ensoli B and Morgan RA (1995) Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes. J Virol 69:4045-4052.
38. Vlassov VV, Balakireva LA and Yakubov LA (1994) Transport of oligonucleotides across natural and model membranes. Biochim Biophys Acta 1197:95-108.
39. Wagner RW (1995) The state of the art in antisense research. Nat Med 1:1116-1118.
40. Webb A, Cunningham D, Cotter F, Clarke PA, Stefano F, Ross P, Corbo M and Dziewanowska Z (1997) BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349:1137-1141.
41. Zhang R, Yan J, Shahinian H, Amin G, Lu Z, Liu T, Saag MS, Jiang Z, Temsamani J and Martin RR (1995) Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther 58:44-53.
42. Zhang Y, Deng Y, Wendt T, Liliensiek B, bierhaus A, Greten J, He W, Cheng B, Hach-Wunderle V, Waldherr R, Ziegler R, Männel D, Stern DM and Nawroth PP (1996) Intravenous somatic gene transfer with antisense tissue factor restores blood flow by reducing tumor necrosis factor expression and fibrin deposition in mouse Meth-A sarcomas. J Clin Invest 97:2213-2224.
43. Zhao Q, Matson S, Herrera CJ, Fisher E, Yu H and Krieg AM (1993) Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev 3:53-66.
44. Zhao Q, Song X, Waldschmidt T, Fisher E and Krieg AM (1996) Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation. Blood 88:1788-1795.
45. Zhao Q, Waldschmidt T, Fisher E, Herrera CJ and Krieg AM (1994) Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. Blood 84:3660-3666.